Psilocybin for Treatment-Resistant Depression: What the Clinical Trials Actually Show

What Is Treatment-Resistant Depression, and Why Does It Matter Here?

Treatment-resistant depression, usually shortened to TRD, describes major depression that has not improved after at least two adequate trials of standard antidepressants. It is common. Roughly a third of people with major depression fall into this category, and for them the usual playbook of switching medications, adding a second drug, or increasing the dose often delivers diminishing returns. This is the population where interest in psilocybin treatment resistant depression research has grown the fastest, because these are precisely the people conventional medicine has struggled to help.

The appeal is not novelty. It is mechanism. Standard antidepressants like SSRIs work gradually, adjusting the availability of serotonin over weeks and requiring daily use. Psilocybin appears to work differently, and that difference is the reason researchers have taken it seriously rather than dismissing it.

How Does Psilocybin Work in the Brain?

Once in the body, psilocybin converts to psilocin, which activates specific serotonin receptors concentrated in the prefrontal cortex, the part of the brain most involved in mood, self-reflection, and rumination. What follows is a temporary window in which the brain becomes unusually flexible, more able to form new connections and loosen entrenched patterns. Researchers call this neuroplasticity, and it appears to be central to why a single experience can produce effects that outlast the drug itself.

This matters because depression, especially the treatment-resistant kind, often involves rigid loops of negative thought. The working theory is that psilocybin briefly destabilizes those loops, and the guided psychotherapy wrapped around the experience helps a person consolidate the change. The compound does not do the work alone. The preparation and integration around it are part of why outcomes in clinical settings differ so much from unsupervised use.

What Do the Clinical Trials Actually Show?

Here is what we know so far, drawn from the studies that have shaped the field.

The most influential trial is the COMP360 Phase 2b study published in the New England Journal of Medicine in 2022. It enrolled 233 people with treatment-resistant depression across ten countries, making it the largest controlled psilocybin trial conducted at that point. Participants received a single dose of 25mg, 10mg, or 1mg of synthetic psilocybin alongside psychological support. For reference, 25mg of synthetic psilocybin is roughly equivalent to 3 to 4 grams of dried Psilocybe cubensis, though clinical trials use pharmaceutical-grade compound for precise dosing. The 25mg group showed a significant reduction in depression scores at three weeks compared with the lowest dose.

The results were promising and incomplete at the same time. Benefit was clear at three weeks, but the gap between dose groups narrowed by twelve weeks, which tells us a single session may not be enough for sustained remission in everyone. The trial also recorded adverse events, including suicidal ideation in a subset of participants, a reminder that this population is seriously ill and that the treatment is not free of risk. Researchers reading the data noted that the people who relapsed tended to do so gradually, which has shaped current thinking about whether a second dose, or ongoing integration work, should become part of the protocol rather than an afterthought.

It helps to put the numbers in human terms. In the 25mg group, a meaningful share of participants were classified as responders at three weeks, meaning their depression scores dropped by at least half, and a smaller group reached full remission. These were people who, by definition, had already failed at least two standard antidepressants before enrolling. For a population that conventional treatment had largely given up on, even a partial and temporary response is clinically significant. The open question is not whether psilocybin can move the needle. It is how long the movement lasts and what kind of follow-up keeps it in place.

Earlier work pointed in the same direction. A 2021 trial at Johns Hopkins, published in JAMA Psychiatry, compared psilocybin-assisted therapy against a waiting list in people with major depressive disorder and found large, rapid reductions in symptoms, with benefits still measurable at one month. A separate open-label study at Imperial College London, published in The Lancet Psychiatry, followed patients with treatment-resistant depression specifically and reported reductions that persisted for several months in some participants. These were small studies without the rigor of a large controlled trial, but together they built the case that the larger COMP360 study was designed to test.

How Strong Is the Evidence, Really?

This is where things get more nuanced, and where honesty serves the reader better than enthusiasm. The evidence for psilocybin in treatment-resistant depression is among the strongest in the entire psychedelic field, which is why the FDA designated it a Breakthrough Therapy. That status speeds review. It does not equal approval.

Several real limitations remain. Blinding is difficult, because most people can tell whether they received an active dose, and that awareness can shape expectations and outcomes. Many trials are small. Long-term durability past six months is still thinly studied. And the structured psychological support built into every trial means we cannot cleanly separate the effect of the compound from the effect of the therapy around it. What we can say with confidence is that the signal is real and consistent across independent research groups. What we cannot yet say is that it works for everyone, or that a single session is sufficient on its own.

One trial illustrates both the promise and the difficulty of reading this research. In 2021, a team at Imperial College London ran a head-to-head comparison of psilocybin against escitalopram, a widely prescribed SSRI, in people with moderate to severe depression. On the study’s main measured outcome, the two treatments did not differ by a statistically significant margin. On several secondary measures, psilocybin appeared to do better, and it worked far faster. Whether you read that as a win for psilocybin or a draw depends heavily on which numbers you weight, and that ambiguity is honest to report. It is also why the field treats any single trial with caution and looks instead at the pattern across many of them.

Where Can Someone Access This Legally?

As of 2026, psilocybin is not an FDA-approved medication. Two pathways exist for legal access in the United States. Oregon operates a regulated psilocybin services program, and Colorado has established a similar framework, both allowing supervised adult use in licensed settings rather than prescription medical treatment. Beyond those two states, the main avenue is enrollment in an active clinical trial. For a state-by-state breakdown of where access stands, see our guide to psychedelic therapy laws in the United States.

This legal reality is the reason professional guidance matters. The difference between a clinical trial outcome and an unsupervised experience is not the mushroom. It is the screening, the preparation, the trained support during the session, and the integration work afterward.

Who Should Be Cautious?

Psilocybin is not appropriate for everyone, and the screening in clinical trials exists for good reason. People with a personal or family history of psychosis or bipolar disorder are generally excluded, because the experience can trigger or worsen those conditions. Certain medications, including some antidepressants, can blunt or complicate the effects. A full list of medical contraindications is covered in our guide to who should pause before pursuing psychedelic therapy. For a broader look at the compound itself, including its forms and dosing, see our complete guide to psilocybin and its therapeutic use, and for the wider clinical picture, our overview of how the conversation around treatment-resistant depression is changing.